Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
AKM Faizul Huq, Md Fashiur Rahman, Md Azizul Islam, Syed A Iqbal, Azizur Rahman, Syed Abul Hassan Md Abdullah, Sheikh MF Akbar
Bangladesh, COVID-19, Management, Zero mortality
Citation Information :
Huq AF, Rahman MF, Islam MA, Iqbal SA, Rahman A, Abdullah SA, Akbar SM. Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepatogastroenterol 2020; 10 (1):31-35.
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country. Aim and objective: This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care. Materials and methods: All patients in this cohort (N: 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days. Results: No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8–21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge. Conclusion: The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country.
Munster VJ, Koopmans M, van Doremalen N, et al. A novel coronavirus emerging in China-key questions for impact assessment. N Engl J Med 2020;382(8):692–694. DOI: 10.1056/NEJMp2000929.
Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis 2020;20(5):e102–e107. DOI: 10.1016/S1473-3099(20)30129-8.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier of transmission of COVID-19. JAMA 2020;323(14):1406–1407. DOI: 10.1001/jama.2020.2565.
Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020. DOI: 10.1002/jmv.25748.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.
Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55(5):2000524. DOI: 10.1183/13993003.00524-2020.
Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020. 1–12. DOI: 10.1038/s41577-020-0311-8.
Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and Multi-Organ Response. Curr Probl Cardiol 2020. 100618. DOI: 10.1016/j.cpcardiol.2020.100618.
World Health Organization. Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, May 11th 2020.
Triple combination therapy shows promise for COVID-19 patients with less severe illnesses. https://abcnews.go.com/Health/triple-combination-therapy-shows-promise-covid-19-patients/story?id=70580878.
Hung IF, Lung KC, Eugene YK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020. DOI: 10.1016/S0140-6736(20)31042-4.
Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7(1):4. DOI: 10.1186/s40779-020-0233-6.
Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020. DOI: 10.1056/NEJMoa2012410.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;57:279–283. DOI: 10.1016/j.jcrc.2020.03.005.
Yao X, Ye F, Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. DOI: 10.1093/cid/ciaa237.
Jaffe S. Regulators split on antimalarials for COVID-19. Lancet 2020;395(10231):1179. DOI: 10.1016/S0140-6736(20)30817-5.
Owens B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. Lancet Rheumatol 2020;2(5):e257. DOI: 10.1016/S2665-9913(20)30089-8.
He HJ, Zhang W, Liang J, et al. Etiology and genetic evolution of canine coronavirus circulating in five provinces of China, during 2018-2019. Microb Pathog 2020;145:104209. DOI: 10.1016/j.micpath.2020.104209.
van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol 2020;83:104351. DOI: 10.1016/j.meegid.2020.104351.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020;80(6):607–613. DOI: 10.1016/j.jinf.2020.03.037.